Published May 18, 2023

The Center for Global Development (CGD) recently published an article entitled “Estimating the Return on Investment of Health Technology Assessment India (HTAIn).” Below are the key takeaways from the article:

• HTAIn has an overall realized return of 9:1 when comparing the total costs of Health Technology Assessment India (HTAIn) to the benefits from three Health Technology Assessments (HTAs)—safety engineered syringes, cervical cancer screening strategies and the Truenat diagnostic platform
• Individual HTA returns ranged from 5:1 to 40:1
• The realized net health benefits produced by these three HTAs is equivalent to over 1380 people living an extra 10 years of healthy life
•  The implementation level of HTA recommendations is critical to maximize the return on investment (ROI). This study used conservative implementation estimates, but if 100 percent implementation (and attribution) is assumed for these HTAs, the overall return of HTAIn could be as high as 71:1

 The full article can be accessed here: https://www.cgdev.org/publication/estimating-return-investment-health-technology-assessment-india-htain